{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T21:59:12Z","timestamp":1792965552959,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.annonc.2025.10.010","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:49:58Z","timestamp":1760798998000},"page":"229-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I\/II KEYMAKER-U03 trial"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-5528","authenticated-orcid":false,"given":"C.","family":"Suarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Yanez Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-3829","authenticated-orcid":false,"given":"T.","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Neiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Keizman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zwenger Kloster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Weickhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-9843","authenticated-orcid":false,"given":"R.","family":"Dziadziuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Suttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Burgents","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.annonc.2025.10.010_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.010_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.annonc.2025.10.010_bib4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.010_bib5","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.010_bib6","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2025.10.010_bib7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2025.10.010_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2025.43.5_suppl.438","article-title":"Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): final results of COSMIC-313","volume":"43","author":"Albiges","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.10.010_bib9","series-title":"WELIREG (belzutifan): Summary of Product Characteristics","year":"2025"},{"key":"10.1016\/j.annonc.2025.10.010_bib10","series-title":"WELIREG (belzutifan): U.S. Prescribing Information. Rahway","year":"2025"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.010_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.010_bib12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.10.010_bib13","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1200\/JCO.2024.42.16_suppl.4537","article-title":"Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): preliminary results of cohort 1 of the phase 1 LITESPARK-010 study","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.10.010_bib14","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/JCO.2023.41.16_suppl.4553","article-title":"Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1\/L1 and VEGF inhibitor: preliminary results of arm B5 of the phase 1\/2 KEYMAKER-U03B study","volume":"41","author":"Albiges","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.010_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.010_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100639","article-title":"A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"7","author":"Garralda","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.010_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annonc.2020.11.020","article-title":"Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer","volume":"32","author":"Perets","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.010_bib18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40265-020-01327-7","article-title":"Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma","volume":"80","author":"Hirsch","year":"2020","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.annonc.2025.10.010_bib19","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1200\/JCO.2012.45.7903","article-title":"Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials","volume":"31","author":"Ji","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2025.10.010_bib20","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"40","key":"10.1016\/j.annonc.2025.10.010_bib21","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2217\/fon-2023-0283","article-title":"LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma","volume":"19","author":"Choueiri","year":"2023","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.010_bib22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:34:55Z","timestamp":1773927295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425049543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0923753425049543"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.010","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I\/II KEYMAKER-U03 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}